Xcell Biosciences Australia PTY LTD (Xcellbio), an affiliate of Xcell Biosciences, Inc., a platform company focused on cell and gene therapy applications, and Royal Perth Hospital announced a ...

Through this agreement, Xcellbio scientists will work with the Royal Perth Hospital team to develop an automated TIL manufacturing process based on AVATAR platform that achieves key goals for cell ...

Adia Nutrition (OTC Pink: ADIA), a trailblazer in advanced healthcare solutions, is excited to announce that its subsidiary, ...

Tumor inflitrating lymphocyte therapies are a promising type of cellular immunotherapy used to treat a broad range of solid ...

Technologies announces its role in supporting Autolus Therapeutics’ FDA approval for AUCATZYL, a recently approved CAR T therapy.

ORIC-944 is a potent, highly selective, orally bioavailable, allosteric inhibitor of PRC2 that demonstrates best-in-class drug properties, including potency, solubility, and pharmacokinetics, with ...

A single molecular switch is essential for blood stem cells to enter an activated, regenerative state in which they produce new blood cells, according to a preclinical study led by Weill Cornell ...

Adia Med, a division of ADIA Nutrition Inc. (OTC Pink: ADIA), is driving a transformative effort to standardize umbilical ...

Long before laboratories and clinical trials, indigenous healers recognized the extraordinary properties of miracle leaf.

A single molecular switch is essential for blood stem cells to enter an activated, regenerative state in which they produce new blood cells, according to a preclinical study led by Weill Cornell ...

“Preclinical findings illuminate the superior GSTP1 binding affinity and inhibitory potency of this novel prodrug ... improved specificity towards cancer cells relative to normal cells and ...